fda statement on compounded semaglutide is moving to restrict mass-marketed GLP-1 products that aren't FDA-approved, warning companies they can't market them as equivalent to approved drugs and signaling stronger enforcement to protect patients from unverified FDA Warns on Certain Forms

Alternative treatment options, dose adjustments, or additional support may be available to address your concerns whilst maintaining diabetes control

These drugs are part of a class of medications known as glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonists or GLP-1 RAs)

A COA should be reviewed for the information it actually documents

This triple action aids in blood sugar regulation, appetite control, and energy expenditure, providing a promising approach to weight loss and metabolic health

Headache in patients initiating GLP-1 receptor agonist therapy: A case series

We want to be upfront with you: the evidence varies considerably